International Urology and Nephrology: Randomized clinical trial of a novel donor-derived cfDNA test to detect rejection in CPV-simulated renal transplant patients
In the follow-up to the baseline study, “Variation in Assessing Renal Allograft Rejection: A National Assessment of Nephrology Practice”, the QURE study of the introduction of the cfDNA diagnostic test in the intervention group, showed an improvement in accuracy by 33%. In addition, the correct biopsy decisions improved by 30% compared to the control group where correct primary diagnosis, biopsy decision, and therapeutic management did not change significantly between rounds.